ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dynamics of anal HPV infection after 9vHPV vaccination in men who have sex with men (MSM) with HIV: A prospective, controlled cohort study.Human vaccines & immunotherapeutics · 2026Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
backgroundMen who have sex with men (MSM) with HIV are at increased risk for anal cancer, largely attributable to persistent HPV infection. However, data on the nonavalent HPV vaccine (9vHPV) in MSM with HIV older than 26 remain sparse.
methodsThis phase IV trial evaluated the immunogenicity, safety, and impact of age and CD4/CD8 ratio on 9vHPV vaccine responses in MSM with HIV up to 35 years. Inclusion criteria were age 16-35, undetectable viral load, and CD4 + counts >200 cells/mm³. Participants received 9vHPV vaccine doses at weeks 0, 8, and 24, and were followed to week 96. Serum samples for immunogenicity, anal HPV DNA testing, and adverse event reports were collected at baseline, week 28, and week 96. Additionally, we investigated potential predictors of vaccine immunogenicity, including age group and CD4/CD8 ratio.
resultsAmong 158 enrolled participants, 138 completed the per-protocol analysis. Seroconversion exceeded 85% for all nine HPV vaccine genotypes at week 96. New infections with vaccine-included genotypes occurred in 24% of participants, predominantly involving HPV-16. The overall clearance rate for any high-risk HPV genotype included in the vaccine was 74% at week 96. Neither older age (≥26 years), lower CD4/CD8 ratio, nadir CD4 or CD4 counts affected immunogenicity. No severe adverse events related to vaccination were recorded.
conclusionsThe 9vHPV vaccine demonstrated robust immunogenicity and encouraging viral clearance rates in MSM with HIV up to 35 years. These findings support extending vaccination beyond 26 years in this high-risk group, emphasizing the additional coverage provided by the 9vHPV formulation. CLINICAL
trial registrationEudraCT number 2018-000215-24.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.